Introgen's Advexin p53 used to treat Li-Fraumeni Syndrome cancer patient

By Lisa Kerner

Erie, Pa., May 8 - Introgen Therapeutics said its Advexin p53 therapy has been successfully used to treat a Li-Fraumeni Syndrome cancer patient on a compassionate use basis under a protocol authorized by the Food and Drug Administration.

The company said it will make its therapy available on a compassionate use basis to qualified Li-Fraumeni Syndrome patients with tumors refractory to standard treatment through protocols at qualifying institutions, according to a news release.

Li-Fraumeni Syndrome is an inherited genetic disorder that increases the risk of developing several types of cancer.

Advexin p53 therapy targets abnormal p53 tumor suppressor function associated with cancer initiation, progression and treatment resistance.

Introgen is an Austin, Texas, biopharmaceutical company focused on cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.